Insider Transactions in Q2 2016 at Cvs Health Corp (CVS)
Insider Transaction List (Q2 2016)
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
May 19
2016
|
Richard J Swift Director |
BUY
Grant, award, or other acquisition
|
Direct |
612
+10.86%
|
$61,200
$100.95 P/Share
|
|
May 19
2016
|
Richard M Bracken Director |
BUY
Grant, award, or other acquisition
|
Direct |
1,095
+21.8%
|
$109,500
$100.95 P/Share
|
|
May 19
2016
|
Nancy Ann Deparle Director |
BUY
Grant, award, or other acquisition
|
Direct |
1,040
+16.29%
|
$104,000
$100.95 P/Share
|
|
May 19
2016
|
David W Dorman Director |
BUY
Grant, award, or other acquisition
|
Direct |
2,823
+3.91%
|
$282,300
$100.95 P/Share
|
|
May 19
2016
|
Anne A. Finucane Director |
BUY
Grant, award, or other acquisition
|
Direct |
1,040
+50.0%
|
$104,000
$100.95 P/Share
|
|
May 19
2016
|
Jean Pierre Millon Director |
BUY
Grant, award, or other acquisition
|
Direct |
1,040
+50.0%
|
$104,000
$100.95 P/Share
|
|
May 19
2016
|
Tony L White Director |
BUY
Grant, award, or other acquisition
|
Direct |
1,040
+4.84%
|
$104,000
$100.95 P/Share
|
|
May 05
2016
|
Larry J Merlo Director |
SELL
Open market or private sale
|
Direct |
38,247
-13.64%
|
$4,015,935
$105.0 P/Share
|
|
May 05
2016
|
Larry J Merlo Director |
BUY
Exercise of conversion of derivative security
|
Direct |
38,247
+12.0%
|
$1,376,892
$36.23 P/Share
|
|
May 05
2016
|
Troyen A Brennan EVP and Chief Medical Officer |
SELL
Open market or private sale
|
Direct |
7,517
-9.75%
|
$789,285
$105.0 P/Share
|
|
May 05
2016
|
Stephen J Gold EVP & CIO |
SELL
Open market or private sale
|
Direct |
9,798
-31.25%
|
$1,028,790
$105.0 P/Share
|
|
May 05
2016
|
Stephen J Gold EVP & CIO |
BUY
Exercise of conversion of derivative security
|
Direct |
9,798
+23.81%
|
$460,506
$47.29 P/Share
|
|
Apr 02
2016
|
Eva C Boratto EVP & CFO |
SELL
Payment of exercise price or tax liability
|
Direct |
3,192
-9.0%
|
$331,968
$104.82 P/Share
|
|
Apr 01
2016
|
Larry J Merlo Director |
BUY
Grant, award, or other acquisition
|
Direct |
38,160
+15.41%
|
$3,968,640
$104.82 P/Share
|
|
Apr 01
2016
|
Larry J Merlo Director |
SELL
Payment of exercise price or tax liability
|
Direct |
17,583
-6.77%
|
$1,828,632
$104.82 P/Share
|
|
Apr 01
2016
|
Jonathan C Roberts EVP & Chief Operating Officer |
BUY
Grant, award, or other acquisition
|
Direct |
21,465
+26.11%
|
$2,232,360
$104.82 P/Share
|
|
Apr 01
2016
|
Helena Foulkes EVP & President-CVS Pharmacy |
BUY
Grant, award, or other acquisition
|
Direct |
9,540
+20.7%
|
$992,160
$104.82 P/Share
|
|
Apr 01
2016
|
Helena Foulkes EVP & President-CVS Pharmacy |
SELL
Payment of exercise price or tax liability
|
Direct |
4,411
-8.77%
|
$458,744
$104.82 P/Share
|
|
Apr 01
2016
|
David M Denton EVP and CFO |
BUY
Grant, award, or other acquisition
|
Direct |
9,540
+5.66%
|
$992,160
$104.82 P/Share
|
|
Apr 01
2016
|
David M Denton EVP and CFO |
SELL
Payment of exercise price or tax liability
|
Direct |
12,902
-8.26%
|
$1,341,808
$104.82 P/Share
|
|
Apr 01
2016
|
Thomas M Moriarty EVP & General Counsel |
BUY
Grant, award, or other acquisition
|
Direct |
9,540
+22.59%
|
$992,160
$104.82 P/Share
|
|
Apr 01
2016
|
Thomas M Moriarty EVP & General Counsel |
SELL
Payment of exercise price or tax liability
|
Direct |
2,972
-10.23%
|
$309,088
$104.82 P/Share
|
|
Apr 01
2016
|
Troyen A Brennan EVP and Chief Medical Officer |
BUY
Grant, award, or other acquisition
|
Direct |
7,155
+16.36%
|
$744,120
$104.82 P/Share
|
|
Apr 01
2016
|
Troyen A Brennan EVP and Chief Medical Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
6,924
-8.24%
|
$720,096
$104.82 P/Share
|
|
Apr 01
2016
|
Stephen J Gold EVP & CIO |
BUY
Grant, award, or other acquisition
|
Direct |
6,439
+13.61%
|
$669,656
$104.82 P/Share
|
|
Apr 01
2016
|
Stephen J Gold EVP & CIO |
SELL
Payment of exercise price or tax liability
|
Direct |
1,546
-6.69%
|
$160,784
$104.82 P/Share
|
|
Apr 01
2016
|
Stephen J Gold EVP & CIO |
SELL
Open market or private sale
|
Direct |
21,922
-52.14%
|
$2,301,810
$105.0 P/Share
|
|
Apr 01
2016
|
Stephen J Gold EVP & CIO |
BUY
Exercise of conversion of derivative security
|
Direct |
21,922
+34.27%
|
$1,030,334
$47.29 P/Share
|
|
Apr 01
2016
|
Eva C Boratto EVP & CFO |
BUY
Grant, award, or other acquisition
|
Direct |
2,862
+14.05%
|
$297,648
$104.82 P/Share
|
|
Apr 01
2016
|
J. David Joyner EVP&President-PharmacyServices |
BUY
Grant, award, or other acquisition
|
Direct |
3,339
+15.66%
|
$347,256
$104.82 P/Share
|
|
Apr 01
2016
|
J. David Joyner EVP&President-PharmacyServices |
SELL
Payment of exercise price or tax liability
|
Direct |
1,155
-1.76%
|
$120,120
$104.82 P/Share
|
|
Apr 01
2016
|
Lisa Bisaccia Former EVP & Chief HR Officer |
BUY
Grant, award, or other acquisition
|
Direct |
5,247
+18.83%
|
$545,688
$104.82 P/Share
|
|
Apr 01
2016
|
Lisa Bisaccia Former EVP & Chief HR Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
4,625
-11.69%
|
$481,000
$104.82 P/Share
|
|
Apr 01
2016
|
Andrew Sussman EVP, Clinical Services |
BUY
Grant, award, or other acquisition
|
Direct |
3,100
+15.19%
|
$322,400
$104.82 P/Share
|
|
Apr 01
2016
|
Andrew Sussman EVP, Clinical Services |
SELL
Payment of exercise price or tax liability
|
Direct |
1,319
-9.56%
|
$137,176
$104.82 P/Share
|
|
Apr 01
2016
|
Andrew Sussman EVP, Clinical Services |
SELL
Open market or private sale
|
Direct |
2,844
-20.48%
|
$298,620
$105.0 P/Share
|
|
Apr 01
2016
|
Robert O. Kraft EVP and President - Omnicare |
BUY
Grant, award, or other acquisition
|
Direct |
3,100
+3.38%
|
$322,400
$104.82 P/Share
|